Newsroom

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Arrowstreet Capital, Limited Partnership (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

LONDON--(BUSINESS WIRE)--EpilepsyGTx, a biotechnology company focused on research and development of cutting-edge gene therapies to treat refractory epilepsy, today announced it has raised $33 million in a Series A financing to advance its lead programme EPY201 through Phase 1/2a clinical trials. The round included investment from XGEN Venture, the British Business Bank, and a global biopharmaceutical company. The funding will enable the delivery of first-in-human Phase 1/2a clinical trials to...

CHICAGO--(BUSINESS WIRE)--Duff & Phelps Investment Management Co., an investment manager of Virtus Investment Partners, Inc., today announced it has been recognized by Pensions & Investments as a 2025 Best Place to Work in Money Management. “We are honored to receive this recognition as a best place to work in money management from Pensions & Investments again this year,” said David D. Grumhaus, Jr., president and chief investment officer of Duff & Phelps. “Because our employees...

LONDON--(BUSINESS WIRE)--  ISIN Code. XS2892385225 Our Ref. MR5459 ISSUE NAME. Santander UK PLC Issue of GBP 1,000,000,000.00 Floating Rate Covered Bonds due September 2029 Series No 89 Tranche 1 MTN INTEREST PERIOD. 12/09/2025 TO 12/12/2025 VALUE DATE. 12/12/2025 INTEREST RATE. 4.4677 PCT NUM OF DAYS. 91 DAY BASIS. ACTUAL/365 FIXED (A005) CURRENCY CODE. GBP TOTAL INTEREST AMT. GBP 11,138,649.32 POOL FACTOR. N/A...

DUBLIN--(BUSINESS WIRE)--The "Australia Doors and Windows Market Size, Share Analysis and Forecast Report (2025-2034)" has been added to ResearchAndMarkets.com's offering. The Australia Doors and Windows Market, valued at AUD 5.73 billion in 2025, is anticipated to reach AUD 8.90 billion by 2034, driven by a consistent CAGR of 4.50%. This growth trajectory highlights significant opportunities and evolving trends within this competitive market. With segments based on material types such as metal...

FORT LEE, N.J.--(BUSINESS WIRE)--Cross River Bank (“Cross River”), a technology infrastructure provider that offers embedded financial solutions, today announced the expansion of its card program capabilities with the launch of its proprietary, in-house card processing engine. With this addition, Cross River joins a select group of financial institutions with complete ownership of the card technology stack — from issuing to processing. Aion Financial Technologies (“Aion”) has been selected as t...

BIRMINGHAM, Ala.--(BUSINESS WIRE)--Regions Financial Corp. announced its Board of Directors authorized the repurchase of up to $3.0 billion of the company’s common stock....

MUSCATINE, Iowa--(BUSINESS WIRE)--HNI Corporation announced today the completion of its acquisition of Steelcase Inc....

LONDON--(BUSINESS WIRE)--  ISIN Code. XS2777451787 Our Ref. MQ7344 ISSUE NAME. Commonwealth Bank of Australia Issue of USD 40,000,000.00 Capped Floating Rate Notes due 13 March 2029 Series 6577Tranche 1 MTN INTEREST PERIOD. 15/09/2025 TO 15/12/2025 VALUE DATE. 15/12/2025 INTEREST RATE. 5.06172 PCT NUM OF DAYS. 91 DAY BASIS. Actual/360 (A004) CURRENCY CODE. USD TOTAL INTEREST AMT. USD 511,796.13 POOL FACTOR. N/A...

瑞士楚格--(BUSINESS WIRE)--(美國商業資訊)-- 專注於生物相似藥研發和生產的一流生物製藥公司Polpharma Biologics欣然宣布，已與巴西企業Libbs Farmacêutica簽署一項具有里程碑意義的授權協議。透過這一策略性合作夥伴關係，Libbs Farmacêutica將獲得一款尖端自身免疫性疾病生物相似藥在快速成長的巴西市場的獨家商業化權利。 Polpharma Biologics將全權負責該生物相似藥的研發和生產工作。Libbs Farmacêutica則擁有該藥物在巴西的獨家商業化、行銷和經銷授權。此次合作開啟了令人振奮的新機會，也彰顯了兩家公司共同的承諾，即為病患提供創新且可及的治療方案。 Polpharma Biologics執行長Anjan Selz表示：「攜這款生物相似藥進軍巴西市場，對Polpharma Biologics而言是重要的一步，也體現了我們持續致力於在全球擴大高品質、可負擔生物治療藥物可及性的使命。Libbs Farmacêutica對巴西市場具有深入的瞭解，與該公司合作讓我們獲得了強大的商業專業知識。結合我們的研發和生產...